REG - Uniphar PLC - Result of AGM

AllotAnnouncement

11/05/2022 17:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220511:nRSK1573La&default-theme=true

RNS Number : 1573L  Uniphar PLC  11 May 2022

AGM Results

 

Dublin, London | 11 May 2022

 

 

Uniphar plc is pleased to announce that at the Annual General Meeting held at
11.00 a.m. today, 11 May 2022, each of the resolutions set out in the Notice
of Annual General Meeting circulated to shareholders and made available on the
Company's website, www.uniphar.ie (http://www.uniphar.ie) , were duly passed
without amendment.

 

Details of votes cast are set out below:

 

       RESOLUTION                                                                TOTAL        FOR          %      AGAINST     %      ABSTAIN
 1     Financial Statements and Reports                                          139,441,694  139,441,694  100    0           0.00   147,705
 2     Final Dividend of €2.9m                                                   139,589,399  139,589,399  100    0           0.00   0
 3(a)  Re-elect Ger Rabbette                                                     139,589,399  135,469,357  97.05  4,120,042   2.95   0
 3(b)  Re-elect Tim Dolphin                                                      139,589,399  138,606,558  99.30  982,841     0.70   0
 3(c)  Re-elect Paul Hogan                                                       139,589,399  130,828,345  93.72  8,761,054   6.28   0
 3(d)  Re-elect Sue Webb                                                         139,589,399  135,343,699  96.96  4,245,700   3.04   0
 3(e)  Re-elect Jeff Berkowitz *                                                 139,589,399  110,242,453  78.98  29,346,946  21.02  0
 3(f)  Re-elect Jim Gaul                                                         139,589,399  132,497,099  94.92  7,092,300   5.08   0
 3(g)  Re-elect Liz Hoctor                                                       139,589,399  135,027,189  96.73  4,562,210   3.27   0
 3(h)  Re-elect Maurice Pratt                                                    139,589,399  131,537,248  94.23  8,052,151   5.77   0
 4     Remuneration of Auditors                                                  85,749,400   74,945,801   87.40  10,803,599  12.60  53,839,999
 5     Allot relevant securities                                                 139,589,399  134,987,663  96.70  4,601,736   3.30   0
 6     Disapplication of pre-emption rights in specified circumstances           139,589,399  139,589,399  100    0           0      0
 7     Disapplication of pre-emption rights in additional circumstances          139,589,399  139,589,399  100    0           0

                                                                                                                                     0
 8     Authorise market purchases of the Company's Ordinary Shares               138,858,398  138,858,398  100    0           0      731,001
 9     Re-issuance of Treasury Shares                                            139,589,399  139,589,399  100    0           0      0
 10    Amendment of the Company's Articles of Association to provide for annual  139,589,399  139,589,399  100    0           0      0
       retirement of all Directors

 

 

 

*The Board notes that Resolution 3(e) passed with a majority of less than 80%
(receiving votes in favour of 78.98%). In accordance with provision 4 of the
UK Corporate Governance Code (the "Code"), the Board confirms that it will
engage with shareholders to understand and discuss the reasons behind the
proxies received against this resolution. An update on the views received from
shareholders and actions taken will be provided within six months of the AGM,
in accordance with the Code.

 

 

--- ENDS ---

 

 

 

 

For further details contact:

 

 Uniphar                                                  +353 (0) 1 428 7777

 Seamus Egan
 Head of Corporate Development and IR                     investor.relations@Uniphar.ie (mailto:investor.relations@Uniphar.ie)

 Davy                                                     +353 (0) 1 679 6363
 (Joint Corporate Broker, Nominated Adviser and Euronext

 Growth Adviser)

 Barry Murphy
 Niall Gilchrist
 Lauren O'Sullivan

 RBC Capital Markets (Joint Corporate Broker)             +44 (0) 20 7653 4000

 Jonathan Hardy
 Jamil Miah

 Stifel Nicolaus Europe Limited (Joint Corporate Broker)  +44 (0) 20 7710 7600

 Matt Blawat
 Ben Maddison
 Francis North

 Q4 PR                                                    +353 (0) 1 475 1444 or
 (Public Relations Adviser to Uniphar)                    +353 87 235 6461

 Iarla Mongey

 

 

 

 

About Uniphar plc

 

Headquartered in Dublin, Ireland, the Uniphar Group is an international
diversified healthcare services business servicing the requirements of more
than 200 multinational pharmaceutical and medical technology manufacturers
across three divisions - Commercial & Clinical, Product Access and Supply
Chain & Retail. The Group is active in Ireland, the UK, the Benelux, the
Nordics, Germany, and the US.

 

The Company's vision is to improve patient access to pharmaco-medical products
and treatments by enhancing connectivity between manufacturers and healthcare
stakeholders. Uniphar represents a strong combination of scale, growth, and
profitability.

 

Commercial & Clinical

In Commercial & Clinical, the Group provides outsourced sales, marketing
& distribution solutions to multinational pharmaceutical and medical
device manufacturers. Active in Ireland, the UK, the Benelux, the Nordics,
Germany and the US, the Group is growing with its clients to provide
pan-European solutions, with a bespoke offering in the US. Uniphar has built
fully integrated digitally enabled customer centric solutions that are
supported by our highly experienced and clinically trained teams, leveraging
our digital technology and insights which allows us to deliver consistently
exceptional outcomes for our clients.

 

Product Access

In Product Access, the Group is growing two distinct service offerings: 1) "On
Demand", which are pharmacy led solutions for sourcing and supplying
unlicensed medicines to meet the needs of both retail and hospital
pharmacists; and 2) "Exclusive Access", which are manufacturer led solutions
for controlling the release of speciality medicines for specifically approved
patient populations in agreed markets. The Group currently delivers product
access solutions on a global basis.

 

Supply Chain & Retail

Uniphar is an established market leader in Ireland with c. 53% market share in
the wholesale/hospital market, supported by a network of 378 owned, franchised
and symbol group pharmacies. The business supports the diverse customer base
through the provision of strong service levels coupled with innovative
commercial initiatives. Supply Chain & Retail is an Irish only business
for the Group, although the manufacturer relationships and infrastructure are
also utilised for the benefit of Commercial & Clinical and Product Access.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGFLFVSEIILLIF